S8 Fig. Anterior gradient 3 (AGR3) had no indication function for therapeutic response of taxane and 5-fluoropyrimidines in non-luminal patients or grade III patients. (A) Overall survival (OS) and progression-free survival (PFS) curves of AGR3 highly expressed non-luminal patients with taxane treatment were shown, respectively (upper panel). OS and PFS curves of AGR3 low expressed non-luminal patients with taxane treatment were shown, respectively (lower panel). (B) OS and PFS curves of AGR3 highly expressed non-luminal patients with 5-fluoropyrimidines treatment were
shown, respectively (upper panel). OS and PFS curves of AGR3 low expressed non-luminal patients with 5-fluoropyrimidines treatment were shown, respectively (lower panel). (C) OS and PFS curves of AGR3 highly expressed non-luminal patients of grade Ⅰ-Ⅱ with taxane treatment were shown, respectively (upper panel). OS and PFS curves of AGR3 low expressed non-luminal patients of grade Ⅰ-Ⅱ with taxane treatment were shown, respectively (lower panel). (D) OS and PFS curves of AGR3 highly expressed non-luminal patients of grade Ⅰ-Ⅱ with 5-fluoropyrimidines treatment were shown, respectively (upper panel). OS and PFS curves of AGR3 low expressed non-luminal patients of grade Ⅰ-Ⅱ with 5-fluoropyrimidines treatment were shown, respectively (lower panel). (E) OS and PFS curves of AGR3 highly expressed IDC patients of grade Ⅲ with taxane treatment were shown, respectively (upper panel). OS and PFS curves of AGR3 low expressed IDC patients of grade Ⅲ with taxane treatment were shown, respectively (lower panel). (F) OS and PFS curves of AGR3 highly expressed IDC patients of grade Ⅲ with 5-fluoropyrimidines treatment were shown, respectively (upper panel). OS and PFS curves of AGR3 low expressed IDC patients of grade Ⅲ with 5-fluoropyrimidines treatment were shown, respectively (lower panel).